Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

A phase I study of neoadjuvant chemotherapy with gemcitabine plus oral S-1 for resectable pancreatic cancer.

Tajima H, Kitagawa H, Tsukada T, Nakanuma S, Okamoto K, Sakai S, Makino I, Furukawa H, Nakamura K, Hayashi H, Oyama K, Inokuchi M, Nakagawara H, Miyashita T, Fujita H, Itoh H, Takamura H, Ninomiya I, Fushida S, Fujimura T, Ohta T.

Mol Clin Oncol. 2013 Jul;1(4):768-772. Epub 2013 May 27.

2.

Pilot study of neoadjuvant chemotherapy with gemcitabine and oral S-1 for resectable pancreatic cancer.

Tajima H, Ohta T, Kitagawa H, Okamoto K, Sakai S, Makino I, Kinoshita J, Furukawa H, Nakamura K, Hayashi H, Oyama K, Inokuchi M, Nakagawara H, Fujita H, Takamura H, Ninomiya I, Fushida S, Tani T, Fujimura T, Ikeda H, Kitamura S.

Exp Ther Med. 2012 May;3(5):787-792. Epub 2012 Feb 13.

3.

A phase I trial of nab-paclitaxel, gemcitabine, and capecitabine for metastatic pancreatic cancer.

Ko AH, Truong TG, Kantoff E, Jones KA, Dito E, Ong A, Tempero MA.

Cancer Chemother Pharmacol. 2012 Dec;70(6):875-81. doi: 10.1007/s00280-012-1979-7. Epub 2012 Sep 28.

PMID:
23053263
4.

A phase I/II study of fixed-dose-rate gemcitabine and S-1 with concurrent radiotherapy for locally advanced pancreatic cancer.

Goji T, Kimura T, Miyamoto H, Takehara M, Kagemoto K, Okada Y, Okazaki J, Takaoka Y, Miyamoto Y, Mitsui Y, Matsumoto S, Sueuchi T, Tanaka K, Fujino Y, Takaoka T, Kitamura S, Okamoto K, Kimura M, Sogabe M, Muguruma N, Okahisa T, Sato Y, Sagawa T, Fujikawa K, Sato Y, Ikushima H, Takayama T.

Cancer Chemother Pharmacol. 2015 Sep;76(3):615-20. doi: 10.1007/s00280-015-2835-3. Epub 2015 Jul 29.

PMID:
26220846
5.

Phase I/II study of gemcitabine as a fixed dose rate infusion and S-1 combination therapy (FGS) in gemcitabine-refractory pancreatic cancer patients.

Morizane C, Okusaka T, Ueno H, Kondo S, Ikeda M, Furuse J, Shinichi O, Nakachi K, Mitsunaga S, Kojima Y, Suzuki E, Ueno M, Yamaguchi T.

Cancer Chemother Pharmacol. 2012 Apr;69(4):957-64. doi: 10.1007/s00280-011-1786-6. Epub 2011 Nov 26.

PMID:
22120961
6.

A phase I study of combination chemotherapy with gemcitabine and oral S-1 for advanced pancreatic cancer.

Ueno H, Okusaka T, Ikeda M, Ishiguro Y, Morizane C, Matsubara J, Furuse J, Ishii H, Nagase M, Nakachi K.

Oncology. 2005;69(5):421-7. Epub 2005 Nov 25.

PMID:
16319514
7.

Phase I/II trial of induction chemotherapy followed by concurrent chemoradiotherapy and surgery for locoregionally advanced pancreatic cancer.

Marti JL, Hochster HS, Hiotis SP, Donahue B, Ryan T, Newman E.

Ann Surg Oncol. 2008 Dec;15(12):3521-31. doi: 10.1245/s10434-008-0152-3. Epub 2008 Oct 2.

PMID:
18830756
8.

Phase I trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer.

Nakamura K, Yamaguchi T, Ishihara T, Kobayashi A, Tadenuma H, Sudo K, Kato H, Saisho H.

Br J Cancer. 2005 Jun 20;92(12):2134-9.

9.

Dose modification and efficacy of nab-paclitaxel plus gemcitabine vs. gemcitabine for patients with metastatic pancreatic cancer: phase III MPACT trial.

Scheithauer W, Ramanathan RK, Moore M, Macarulla T, Goldstein D, Hammel P, Kunzmann V, Liu H, McGovern D, Romano A, Von Hoff DD.

J Gastrointest Oncol. 2016 Jun;7(3):469-78. doi: 10.21037/jgo.2016.01.03.

10.

Phase I study of escalating doses of oxaliplatin in combination with fixed dose gemcitabine in patients with non-small cell lung cancer.

Bidoli P, Stani SC, Mariani L, De Candis D, Cortinovis D, Aglione S, Zilembo N, Toffolatti L, Formisano B, Bajetta E.

Lung Cancer. 2004 Feb;43(2):203-8.

PMID:
14739041
11.

Phase I trial of combination chemotherapy with gemcitabine, cisplatin, and S-1 in patients with advanced biliary tract cancer.

Watanabe A, Kida M, Miyazawa S, Iwai T, Okuwaki K, Kaneko T, Yamauchi H, Takezawa M, Imaizumi H, Koizumi W.

World J Gastroenterol. 2015 May 21;21(19):5979-84. doi: 10.3748/wjg.v21.i19.5979.

12.

Phase I and pharmacokinetic study of two sequences of gemcitabine and docetaxel administered weekly to patients with advanced cancer.

Bhargava P, Marshall JL, Fried K, Williams M, Lefebvre P, Dahut W, Hanfelt J, Gehan E, Figuera M, Hawkins MJ, Rizvi NA.

Cancer Chemother Pharmacol. 2001 Aug;48(2):95-103.

PMID:
11561784
13.

Phase I study of neoadjuvant chemoradiotherapy with S-1 plus biweekly cisplatin for advanced gastric cancer patients with lymph node metastasis: -KOGC04-.

Matsuda S, Takahashi T, Fukada J, Fukuda K, Kawakubo H, Saikawa Y, Kawaguchi O, Takeuchi H, Shigematsu N, Kitagawa Y.

Radiat Oncol. 2014 Jan 8;9:9. doi: 10.1186/1748-717X-9-9. Erratum in: Radiat Oncol. 2014;9:140.

14.

Phase I study of oxaliplatin, full-dose gemcitabine, and concurrent radiation therapy in pancreatic cancer.

Desai SP, Ben-Josef E, Normolle DP, Francis IR, Greenson JK, Simeone DM, Chang AE, Colletti LM, Lawrence TS, Zalupski MM.

J Clin Oncol. 2007 Oct 10;25(29):4587-92.

PMID:
17925553
15.

S-1 plus gemcitabine chemotherapy followed by concurrent radiotherapy and maintenance therapy with S-1 for unresectable pancreatic cancer.

Ke QH, Zhou SQ, Yang JY, Du W, Liang G, Lei Y, Luo F.

World J Gastroenterol. 2014 Oct 14;20(38):13987-92. doi: 10.3748/wjg.v20.i38.13987.

16.

[Examination of resectable and borderline pancreatic cancer treated with neoadjuvant chemoradiation therapy].

Mataki Y, Shinchi H, Maemura K, Kurahara H, Kawasaki Y, Desaki R, Ueno S, Sakoda M, Iino S, Higashi M, Takao S, Natsugoe S.

Gan To Kagaku Ryoho. 2013 Nov;40(12):1637-40. Japanese.

PMID:
24393873
17.

A phase I study for adjuvant chemotherapy of gemcitabine plus S-1 in curatively resected patients with biliary tract cancer: adjusting the dose of adjuvant chemotherapy according to the surgical procedures.

Takahara T, Nitta H, Hasegawa Y, Itou N, Takahashi M, Nishizuka S, Wakabayashi G.

Cancer Chemother Pharmacol. 2012 May;69(5):1127-33. doi: 10.1007/s00280-011-1805-7. Epub 2011 Dec 30.

PMID:
22207029
18.

Neoadjuvant chemotherapy with gemcitabine and S-1 for resectable and borderline pancreatic ductal adenocarcinoma: results from a prospective multi-institutional phase 2 trial.

Motoi F, Ishida K, Fujishima F, Ottomo S, Oikawa M, Okada T, Shimamura H, Takemura S, Ono F, Akada M, Nakagawa K, Katayose Y, Egawa S, Unno M.

Ann Surg Oncol. 2013 Nov;20(12):3794-801. doi: 10.1245/s10434-013-3129-9. Epub 2013 Jul 10.

PMID:
23838925
19.

A dose escalation study of docetaxel plus capecitabine in combination with gemcitabine in patients with advanced solid tumors.

Amarantidis K, Houhouli K, Papatheodorou K, Miloussis A, Matthaios D, Chatzaki E, Lyrantzopoulos N, Tsaroucha A, Tentes A, Kakolyris S.

Oncol Res. 2006;16(6):281-7.

PMID:
17476973
20.

Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study).

Heinrich S, Pestalozzi B, Lesurtel M, Berrevoet F, Laurent S, Delpero JR, Raoul JL, Bachellier P, Dufour P, Moehler M, Weber A, Lang H, Rogiers X, Clavien PA.

BMC Cancer. 2011 Aug 10;11:346. doi: 10.1186/1471-2407-11-346.

Supplemental Content

Support Center